113 related articles for article (PubMed ID: 25328951)
1. Sunitinib for atypical and anaplastic meningioma.
Rahman A
Lancet Oncol; 2014 Sep; 15(10):e424. PubMed ID: 25328951
[No Abstract] [Full Text] [Related]
2. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
3. Atypical and anaplastic meningiomas treated with bevacizumab.
Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
[TBL] [Abstract][Full Text] [Related]
4. Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
Yoshikawa A; Nakada M; Ohtsuki S; Hayashi Y; Obuchi W; Sato Y; Ikeda C; Watanabe T; Kawahara Y; Hasegawa T; Sabit H; Kita D; Hayashi Y; Nakanuma Y; Terasaki T; Hamada JI
Neuropathol Appl Neurobiol; 2012 Feb; 38(1):105-10. PubMed ID: 21696419
[No Abstract] [Full Text] [Related]
5. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Lou E; Sumrall AL; Turner S; Peters KB; Desjardins A; Vredenburgh JJ; McLendon RE; Herndon JE; McSherry F; Norfleet J; Friedman HS; Reardon DA
J Neurooncol; 2012 Aug; 109(1):63-70. PubMed ID: 22535433
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
Pellerino A; Soffietti R; Rudà R
J Neurooncol; 2016 Mar; 127(1):201-3. PubMed ID: 26614515
[No Abstract] [Full Text] [Related]
7. Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.
Marosi C
Neuro Oncol; 2015 Jan; 17(1):7-8. PubMed ID: 25378633
[No Abstract] [Full Text] [Related]
8. Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
Kessler RA; Garzon-Muvdi T; Yang W; Weingart J; Olivi A; Huang J; Brem H; Lim M
World Neurosurg; 2017 May; 101():47-56. PubMed ID: 28143726
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.
Chohan MO; Ryan CT; Singh R; Lanning RM; Reiner AS; Rosenblum MK; Tabar V; Gutin PH
Neurosurgery; 2018 Jun; 82(6):824-832. PubMed ID: 28645194
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
[TBL] [Abstract][Full Text] [Related]
13. Role of hydroxyurea as an adjuvant treatment after Gamma knife radiosurgery for atypical (WHO grade II) meningiomas.
Abdel Karim K; El Shehaby A; Emad R; Reda W; El Mahdy M; Ghali R; Nabeel A
J Egypt Natl Canc Inst; 2018 Jun; 30(2):69-72. PubMed ID: 29691095
[No Abstract] [Full Text] [Related]
14. Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis.
Spille DC; Heß K; Sauerland C; Sanai N; Stummer W; Paulus W; Brokinkel B
World Neurosurg; 2016 Sep; 93():346-54. PubMed ID: 27344043
[TBL] [Abstract][Full Text] [Related]
15. Early gross recurrence of atypical meningioma.
Stark AM; Buhl R; Mehdorn HM
J Neurooncol; 2005 Nov; 75(2):223-4. PubMed ID: 16132505
[No Abstract] [Full Text] [Related]
16. Bevacizumab-induced regression of anaplastic meningioma.
Puchner MJA; Hans VH; Harati A; Lohmann F; Glas M; Herrlinger U
Ann Oncol; 2010 Dec; 21(12):2445-2446. PubMed ID: 21041375
[No Abstract] [Full Text] [Related]
17. Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit.
Pant S; Tonse R; Kannan S; Moiyadi A; Shetty P; Epari S; Sahay A; Sastri GJ; Jalali R; Gupta T
Pract Radiat Oncol; 2018; 8(5):e275-e284. PubMed ID: 29861352
[TBL] [Abstract][Full Text] [Related]
18. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free Survival and Factors Associated with Postoperative Recurrence in 126 Patients with Atypical Intracranial Meningioma.
Phonwijit L; Khawprapa C; Sitthinamsuwan B
World Neurosurg; 2017 Nov; 107():698-705. PubMed ID: 28838877
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
